HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant-Reference-Cited by-同舟云学术

HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant

Published:2015-04 Issue:1 Volume:137 Page:160-166
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Growdon Whitfield B.,Groeneweg Jolijn,Byron Virginia,DiGloria Celeste,Borger Darrell R.,Tambouret Rosemary,Foster Rosemary,Chenna Ahmed,Sperinde Jeff,Winslow John,Rueda Bo R.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference40 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Endometrial cancer;Amant;Lancet,2005

3. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers;Hamilton;Br J Cancer,2006

4. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer;Chan;J Gastrointest Surg,2012

5. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications;Hechtman;Arch Pathol Lab Med,2012

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions;Gynecologic Oncology;2024-06

2. Global trends in BRCA-related breast cancer research from 2013 to 2022: A scientometric analysis;Frontiers in Oncology;2023-07-05

3. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions;Cancer and Metastasis Reviews;2023-06-27

4. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study;JCO Precision Oncology;2023-04

5. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma;Pathology;2023-02